Clinical Trial Detail

NCT ID NCT02675231
Title A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab

Abemaciclib + Trastuzumab

Abemaciclib + Fulvestrant + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST